Roche, Inovio to Develop Prostate Cancer, Hepatitis B Vaccines

Inovio Pharmaceuticals Inc. could earn more than $400 million through a partnership with Roche Holding AG to develop vaccines that target prostate cancer and hepatitis B. Read the full story